| Symbol | ISLMF |
|---|---|
| Name | INSILICO MEDICINE CAYMAN TOPCO |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | China HK Unit 310, 3/F, Building 8W, Phase 2 Hong Kong Science Park |
| Telephone | — |
| Fax | — |
| — | |
| Website | https://insilico.com/ |
| Incorporation | KY |
| Incorporated On | 2018 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | NOT AVAILABLE |
| Reporting Status | International Reporting: Hong Kong Stock Exchange |
| CIK | 0001789097 |
| Description | InSilico Medicine Cayman TopCo operates as an artificial intelligence (AI)-based biotech company that helps to develop and manufacture novel drugs in Hong Kong, the United States, the United Kingdom, Mainland China, and internationally. The company develops solutions to discover and develop drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. It also offers Pharma.AI platform, a commercially end-to-end generative Al software and automation platform which is designed to enhance the quality and productivity of pharmaceutical research. Additional info from OTC: |
No news found.